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1. Summary 
Purpose:  The current study aimed at identifying and quantifying critical drug interactions in 
neurological inpatients using Clinical Decision Support Software (CDSS). Reclassification of 
interactions with a focus on clinical management aimed at reducing over-alerting and enhancing 
the efficacy of CDSS to improve medication safety in clinical practice. 
Methods:  Cross-sectional study in consecutive patients admitted to the neurology ward of a 
tertiary care hospital. We developed a customized interface for mass analysis with the CDSS 
MediQ, which we used for automated retrospective identification of drug interactions during the 
first day of hospitalization. Interactions were reclassified according to the Zurich Interaction 
System (ZHIAS) that incorporates the Operational Classification of Drug Interactions (ORCA). 
Dose adjustments for renal impairment were also evaluated. 
Results:  In 484 patients with 2’812 prescriptions MediQ generated 8 “high danger”, 518 
“average danger” and 1’233 “low danger” interaction alerts. According to ZHIAS 6 alerts involved 
contraindicated and 33 provisionally contraindicated combinations, 327 a conditional, and 1’393 a 
minimal risk of adverse outcomes. 35 patients (6.2%) had at least one combination that was at 
least provisionally contraindicated. ZHIAS also provides categorical information on expected 
adverse outcomes and management recommendations, which are presented in detail. We 
identified 13 prescriptions without recommended dose adjustment for impaired renal function. 
Conclusions:  MediQ detected a large number of drug interactions with variable clinical 
relevance in neurological inpatients. ZHIAS supports the selection of those interactions that 
require active management, and the effects of its implementation into CDSS on medication safety 
should be evaluated in future prospective studies.Einleitung und Ziele 
2. Introduction and goals 
A number of studies have evaluated the risk of critical drug interactions and related adverse drug 
events (ADE) and costs in hospitalized patients.1-5 Most studies were conducted on general 
medical, surgical and intensive care wards, but clinical data on medication safety in neurological 
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inpatients is sparse, and the clinical significance and preventability of ADE in neurology therefore 
remain unclear. 
Clinical Decision Support Software (CDSS) can sensitively detect drug interactions and has been 
touted as a powerful tool to improve medication safety in clinical practice.6 7 Furthermore CDSS 
may also be an efficacious tool to improve prescribing compliance with recommended doses, 
particularly in patients with renal impairment.8 9 However, in spite of these convincing theoretical 
advantages, some recent studies concluded that over-alerting and lack of practical management 
recommendations often cause physicians to disregard even severe alerts.10-13 One review 
concluded that between 49% and 96% of automated alerts are routinely ignored or overridden.14 
This “alert fatigue” strongly limits the acceptance of CDSS and therefore its efficacy in improving 
medication safety in daily practice.15 16 Furthermore, there exists no gold standard for the 
classification of interactions in CDSS, and most systems use their own variation of a “traffic light 
system” with 3 major overall severity classes. However, it remains largely unknown how such 
severity grading correlates with clinical relevance, i.e. the need for active management of 
interactions in individual patients. The Operational Classification of Drug Interactions (ORCA) 
addresses this issue and particularly focuses on clinical management of interactions.17 18 
Nevertheless, there are only few studies that aimed at evaluating specific strengths and 
limitations of different CDSS and their classifications, and even those mostly worked with pre-
selected specific drug combinations rather than clinical data.19-21 This situation emphasizes the 
need for further evaluations of CDSS using real-life prescription data from representative 
populations and settings. 
The current study therefore had the following aims: first, identification and quantification of critical 
drug interactions and dosing errors in a representative neurological inpatient population under 
natural conditions; second, reclassification of interactions by using a widely accepted system that 
focuses on clinical relevance of interactions and reduces over-alerting; third, further development 
of such a system into a classification with additional dimensions and variables that can be easily 
displayed in CDSS and therefore facilitate the recognition and active management of interactions 
in clinical practice. 
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3. Methods 
Study population, data collection and study design 
We conducted a cross-sectional study in all patients admitted to the neurology ward of the 
University Hospital Zurich between 1 January and 31 December 2007. There were no exclusion 
criteria except admissions for less than 24 hours. Figure 1 shows an overview of the study 
procedures. Pharmacotherapy within the first 24 hours after admission, demographic data, 
medical diagnoses and laboratory test results were retrospectively retrieved for each patient from 
the hospital’s clinical information system. After splitting medications that contained several active 
substances into individual components, we matched all substances to their corresponding ATC 
codes. Subsequently we analyzed the frequency and severity grading of drug interactions using 
the commercially available CDSS MediQ and then reclassified those interactions according to a 
new system. Furthermore, we analyzed compliance with recommended dose adjustments in 
patients with an estimated GFR <60 ml/min based on MediQ alerts, Aronoff’s Drug Prescribing in 
Renal Failure,22 and the manufacturers’ national prescribing information. 
The regional ethics committee had approved the study protocol including access to the hospital’s 
clinical information system for study purposes. 
MediQ and development of a customized interface for mass analysis of drug interactions 
MediQ is a commercial CDSS for use via the Internet that features detailed comments on more 
than 20’000 drug interactions involving about 2’000 specific substances.23 The user manually 
enters concomitantly prescribed drugs for individual patients, and MediQ subsequently identifies 
interactions and classifies them according to a four-level hierarchical severity grading described 
as: 3 = “strong” interaction with a “high danger” of resulting ADEs; 2 = “clinically relevant” 
interaction with an “average danger”; 1 = an interaction that is “relevant in exceptional cases” and 
with a “low danger”; 0 = “no interaction”. MediQ also provides detailed free text information for 
each interaction and additional tables showing interacting pharmacokinetic and 
pharmacodynamic effects. 
Because the manual entry of prescriptions for each patient would not be efficient for our 
purposes, we developed, in collaboration with the programmer of the MediQ application, a 
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customized data interface for mass analysis. This allowed us to upload a single structured text file 
over the Internet that contained the prescription information for several thousand patients at a 
time. Exactly the same analyses as for the usual Internet application were then executed on the 
MediQ server. Results could be downloaded and imported into statistical software for further 
analyses. MediQ’s knowledge database is continuously updated, and the interaction analyses 
presented here were all executed in October 2010. 
Zurich Interaction System (ZHIAS) classification 
ZHIAS is an extended drug interaction classification system that was developed at our 
department during the conduct of this and other related studies. It features 4 major dimensions 
plus free text fields. The first dimension uses the well-documented five-level grading according to 
the Operational Classification of Drug Interactions (ORCA) criteria.17 24 Briefly, ORCA’s five 
operational levels are defined as follows: Grade 1 = “contraindicated combination”; the risk 
associated with the drug interaction always outweighs the benefit. Grade 2 = “provisionally 
contraindicated”; the combination should be avoided unless the interaction is desired or no 
alternative is available, monitoring may be necessary. Grade 3 = “conditional risk”; monitoring or 
alternatives should be considered. Grade 4 = “minimal risk”; no special action is needed. Grade 5 
= “no interaction”. ZHIAS’ other 3 major dimensions use dichotomous variables that relate to 
patient management, interaction mechanisms and expected adverse effects. For the current 
study an expert panel consisting of one pharmacist (OZ), one senior psychiatrist (MG), two senior 
neurologists (AS, RG), and one senior clinical pharmacologist (SR) discussed the ZHIAS 
classifications of identified interactions until common agreement was achieved. For our 
assessments we referred to original and secondary literature, including but not limited to Hansten 
and Horn’s Drug Interactions: analysis and management,24 and Stockley’s Drug Interactions.25 
Data analysis 
Data analysis was descriptive with presentation of results in text, tables and figures, and 
calculation of medians, means and proportions as appropriate. Data management and analyses 
were performed with STATA Version 11.1 for MacOS X (STATA corporation, College Station, TX, 
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USA), SPSS Version 19 for Windows (SPSS, Inc., Chicago, IL, USA), and various versions of 
Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). 
4. Results 
During the study period 566 patients were admitted for at least 24 hours to the neurology ward. 
These patients received a total of 2’882 prescriptions involving 298 distinct substances with a 
median of 4 prescriptions per patient (range 0 - 21). Seventy-five patients (13.3%) had only one 
or no prescription and therefore did not qualify for an interaction analysis. Seven substances 
(nicomorphine, immunoglobulin, carnitine, alkali metal salts, clavulanic acid, tazobactam and 
benserazide) were excluded from further analyses because appropriate codes were missing in 
the MediQ database. We also excluded 2 unspecified herbal preparations and dietary 
supplements with unclear composition, and 4 infusion solutions, accounting for a total of 190 
prescriptions. Consequently another 7 patients had only one or no prescription and were 
therefore not analyzed for drug interactions. Eventually, out of 2’812 individual prescriptions 
among the remaining subgroup of 484 patients, 2’622 (93.2%) were analyzed for interactions 
using MediQ. 
Characteristics of all 566 patients and the subgroup of 484 patients analyzed for drug interactions 
are presented in Table 1. Overall patient characteristics were closely similar between those 
groups. Among the 484 patients analyzed for drug interactions the median number of 
concomitantly prescribed drugs per patient was 5 (range 2 - 21). Frequency of prescriptions by 
drug classes is shown in Table 2. Anticoagulants including low-dose heparins were the most 
commonly used drugs, prescribed to over 50% of patients. 
Results of the automated drug interaction analyses using MediQ and subsequent reclassification 
according to ZHIAS are presented in Tables 3-6 and Figure 2. Including “danger 0” comments 
MediQ issued an average number of 5.7 alerts per patient, with a maximum of 45 comments 
found in a single patient with 16 concomitant substances. The average number of interaction 
alerts per patient when limited to grade 1-3 was 3.6 (maximum 24 alerts per patient). Drug 
classes most frequently associated with clinically significant interactions according to ZHIAS were 
anticonvulsants (90 cases of ORCA level 1-3 interactions), followed by cardiovascular agents (77 
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cases), antidepressants (51 cases), anxiolytics and sedatives (50 cases), other analgesics (36 
cases), and antipsychotics (35 cases). Original MediQ grading of interactions and reclassification 
according to ORCA criteria is shown in Table 3, and distribution of patients by interactions with 
different grading according to MediQ and after reclassification using ZHIAS in Figure 2. A 
summary of the extended ZHIAS classifications of all interactions classified as ORCA grade 1, 2 
or 3 is presented in Table 4. Increased drug effects accounted for the majority of all interactions, 
the most common expected adverse events being bleeding, sedation and other CNS effects, 
cardiac arrhythmias and electrolyte disturbances. All specific interactions with the highest rating 
according to MediQ or ZHIAS, as well as the most common interactions with intermediate grading 
identified in our study are presented in Tables 5 and 6, respectively, along with their 
classification and expected adverse events. All combinations with the highest rating occurred only 
once in the study population. Of particular interest, Table 6 shows that the combination of 
acetylsalicylic acid and heparins occurred in almost one third of all patients and was classified by 
MediQ as “average danger” with the label “clinically significant”, whereas ZHIAS classified the 
combination as probably desired with a mere conditional risk. 
Among 554 patients with available GFR estimates 66 (11.7%) had moderate (GFR 30 - 59 
ml/min), and 4 (0.7%) severe (GFR <30 ml/min) renal impairment. They had a total of 458 
prescriptions for 135 distinct substances. MediQ indicated a need for dose adjustment in case of 
impaired renal function for 36 (26.7%) out of the 135 individual substances, accounting for 186 
(40.6%) of the 458 prescriptions. Aronoff’s “Drug Prescribing in Renal Failure” recommended 
dose adjustments for 44 substances (32.6%), accounting for 206 prescriptions (45%). We found 
13 prescriptions (6.3%) for 11 individual patients where the dose was higher than recommended 
and assessed the risk of a resulting ADE as major in 6, and minor in 7 patients. 
5. Diskussion 
The results of this study are of interest from two main points of view. First, we identified frequent 
and critical drug interactions that actually occurred under natural conditions in a representative 
neurological inpatient population. Second, in order to achieve this task we developed two 
10 
 
innovative methods, i.e. a customized interface for mass analysis of interactions with CDSS, and 
an extended drug interaction classification. 
MediQ covered 291 out of 298 (97.7%) substances prescribed in the studied population, and 
based on its comprehensive interaction database it generated an average number of 5.7 alerts 
per patient. Overall, we found the comments to be informative and of good quality. On the other 
hand, extrapolation to a typical hospital setting where a resident may be in charge of 16 patients 
at a time implies that this resident would be exposed to approximately 100 alerts and comments 
each day issued by MediQ or any other CDSS with comparable sensitivity. Accordingly serious 
concerns have been expressed that such a high number of alerts typically leads to non-
discriminative overriding even of severe alerts and therefore compromises the efficacy of CDSS 
to improve medication safety.15 26 Furthermore, although the display of alerts can usually be 
filtered based on a system’s severity grading, our results suggest that this is not a reliable 
measure to select those cases where a drug interaction requires active management. The ORCA 
classification has been designed with this issue in mind, and we have now extended this 
classification and retrospectively studied its performance in a real-life population. 
Table 4 and Figure 2 show how ZHIAS may help to focus a physician’s attention on information 
that is relevant for clinical management of individual patients. After reclassification only 35 
patients (6.2%) received alerts that indicate a “contraindicated or “provisionally contraindicated” 
interaction according to ZHIAS. This may be compared to 230 patients (40.6%) that fall into 
MediQ’s top 2 severity classes of “high” and “average” danger. Such a direct comparison may be 
limited by the different nature of the two systems, but a look at individual combinations provides 
further insight into the different weighting of the two systems. Referring to the original ORCA 
concept we classify combinations as contraindicated when the risk always outweighs the benefit, 
rather than on the assumed probability and severity of the expected consequence.17 Therefore 
assignments can also be primarily driven by limited evidence on a combination’s benefit, which is 
the case for gingko biloba when combined with acetylsalicylic acid, or on an almost complete lack 
of efficacy, for example when oral midazolam is combined with carbamazepine.27 Similarly, a 
combination of two benzodiazepines may not imply a high risk of an adverse drug event, but the 
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classification as „provisionally contraindicated“ according to ZHIAS points towards an 
unnecessary risk, unless one consciously combines different benzodiazepines based on the 
differences in their pharmacokinetics and therefore indications, e.g. long-acting for anxiolysis 
during the day and short-acting for sleep induction. 
However, even such a reclassification from MediQ to ORCA does not use the full potential of the 
original ORCA concept to provide more specific management recommendations.17 ZHIAS 
therefore features additional categorical information on management, expected adverse drug 
effects and thereby also on possible risk factors. The coexistence of several risk factors may 
even be a necessary requirement for the occurrence of an adverse drug effect in an individual 
patient. For example ZHIAS can readily provide the information that a patient receiving 
metoprolol and amiodarone should be monitored for hypotension and bradycardia, or that this 
combination should a priori be avoided if those signs are already preexisting. Another example 
that demonstrates the added value of ZHIAS is the combination of heparin plus low dose aspirin. 
MediQ classifies the risk as “average” and “clinically relevant”. In contrast ZHIAS considers the 
risk only as conditional, and the extended management classification readily indicates that this is 
usually a desired combination with a favorable risk-benefit ratio.  Storage of this information as a 
categorical variable has two practical advantages. First, a ZHIAS-based CDSS could deliver such 
categorical information through a limited number of corresponding icons at first glance to the 
treating physician. This would support both, active management for prevention of adverse effects, 
as well as their recognition as such if they have already occurred in an individual patient. Second, 
the information could be linked to electronic patient data that relates to the potential adverse 
effects. Refined alert algorithms can then be individualized, and the resulting alerts could be more 
specific for each patient and thus further reduce over-alerting. For example hyponatremia or QTc 
prolongation could be displayed with a high level of importance if they are recognized as a 
potential adverse effect of a prescribed combination and if the CDSS automatically receives the 
information that they are indeed present in an individual patient. 
Another intriguing perspective that arises from our study is the possibility to conduct highly 
efficient mass analyses, which require solutions such as our customized interface between 
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electronic prescription data and CDSS. Retrospective analyses can then guide the development 
of prospective preventive strategies that target those drug interactions that were identified to 
occur with a certain frequency and actually lead to adverse drug effects in a given setting. Our 
results support the view that a limited number of critical combinations account for a large part of 
all critical interactions in practice. Consequently, during our regular neurology ward rounds we 
are now able to address particularly those drug interactions that the current study identified to be 
frequent and clinically relevant in this setting. Whether such an approach will indeed be able to 
reduce ADE must be further investigated, but previous studies have shown that the selection of 
specific targets and application of targeted electronic interventions on pharmacotherapy can 
indeed be an efficacious and efficient method in order to improve clinical outcomes.28 
Our study is also subject to some important limitations. First, it was not designed to search for 
interactions beyond those identified by MediQ, although we plan to address this point in future 
studies that compare several different CDSS. Neither did we determine the frequency of ADE 
associated with drug interactions, which would have been difficult in retrospective and also be 
underpowered given the limited number of studied patients. Furthermore, the absence of a gold 
standard is a challenge for all attempts to classify drug interactions. Poor accordance between 
different systems has been demonstrated,29-31 and even within the same system there is interrater 
variability.18 32 This also applies to ORCA, where our personal assessment as part of ZHIAS 
sometimes deviated from Hansten & Horn’s own ORCA class. However, we tried to minimize the 
subjective component by setting up an expert panel where we also used widely recognized and 
regularly updated reference texts as a basis for our judgments. Finally, we had to limit our study 
period to the end of 2007 because thereafter the regular presence of clinical pharmacologists at 
ward rounds would have affected the “natural” frequency of interacting prescriptions. 
In conclusion, our study was able to identify drug interactions in neurological inpatients with a 
new and highly efficient solution for CDSS-based automated mass analysis. Subsequent 
reclassification of interactions according to a new extended classification allowed us to select a 
smaller number of contraindicated combinations and interactions that likely require active clinical 
management, and to describe expected adverse effects that can also point towards associated 
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risk factors. The implementation of ZHIAS in CDSS may reduce over-alerting and improve 
usability and efficacy of CDSS to prevent ADE in clinical practice, which should be evaluated in 
future prospective studies. 
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7. Tables 
Table 1 - Characteristics of the study population 
 
Characteristics 
All 
patients  
Patients analyzed for drug 
interactions1 
 n % n % 
     
Total 566 100 484 100 
 
Sex 
    
    Female 314 55.5 264 54.5 
    Male 252 44.5 220 45.5 
     
Age category (years)     
    <25 22 3.9 19 3.9 
    25-44 125 22.1 96 19.8 
    45-64 205 36.2 172 35.5 
    65-84 200 35.3 184 38.0 
    85 and older 14 2.5 13 2.7 
     
Primary admission diagnosis 2     
    Cerebrovascular events 227 40.1 206 42.6 
    Inflammatory and demyelinating diseases 78 13.8 67 13.8 
    Epilepsy / seizures 55 9.7 45 9.3 
    Headache, migraine and other pain 
syndromes 
46 8.1 39 8.1 
    Cognition, perception, speech and visual 
disturbance 
45 8.0 34 7.0 
    Parkinson’s disease / movement disorders 36 6.4 29 6.0 
    Malignant or benign brain neoplasms 28 4.9 25 5.2 
    Paralytic syndromes 26 4.6 19 3.9 
    Other 25 4.4 20 4.1 
     
At least one secondary psychiatric diagnosis 102 18.0 84 17.4 
     
Renal function (MDRD-GFR)     
    ≥60 mL/min 484 85.5 412 85.1 
    30-60 mL/min 66 11.7 63 13.0 
    <30 mL/min 4 0.7 4 0.8 
    No information available 12 2.1 5 1.0 
     
     
1 Drug interactions were not analyzed in 75 patients that received only one or no drug, and in 
another 7 patients that received only one or no drug that was contained in the MediQ database. 
2 Only one primary diagnosis per patient 
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Table 2 - Pharmacotherapy within 24 hours after admission in 484 patients analyzed for drug 
interactions by MediQ 
Drugs n 
prescriptions 
n patients with 
prescriptions 
 n % n % 
Total 2’8121 100 484 100 
     
Anticoagulants (including low-dose heparins) 316 11.2 270 55.8 
Vitamins and mineral supplements 267 9.5 74 15.3 
Acetylsalicylic acid (low dose) 197 7.0 197 40.7 
Analgesics and antipyretics 186 6.6 145 30.0 
Renin-angiotensin-aldosterone system inhibitors 
and diuretics 183 6.5 120 24.8 
Antipsychotics, anxiolytics, sedatives and 
hypnotics 181 6.4 144 29.8 
Anticonvulsants 177 6.3 115 23.8 
Lipid-lowering agents 163 5.8 157 32.4 
Other blood modifiers/volume expanders 143 5.1 133 27.5 
Other cardiovascular agents 133 4.7 107 22.1 
Proton pump inhibitors 124 4.4 124 25.6 
Hormones 116 4.1 109 22.5 
Antidepressants 98 3.5 86 17.8 
Anti-infective agents 83 3.0 53 11.0 
Other nervous system agents 76 2.7 65 13.4 
Other gastrointestinal agents 70 2.5 52 10.7 
Anti-Parkinson agents 62 2.2 24 5.0 
Antidiabetic agents 56 2.0 38 7.9 
Ophthalmic and respiratory tract agents 51 1.8 30 6.2 
Special nutrition and herbal medicines 48 1.7 46 9.5 
Antineoplastic and immunological agents 31 1.1 28 5.8 
Other 51 1.8 46 9.5 
1Out of 2’812 individual prescriptions, only 2’622 (93.2%) were later analyzed for interactions by 
MediQ because 13 substances accounting for 190 prescriptions were not contained in its 
database (see results for details). 
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Table 3 - Identification and grading of interactions by MediQ and subsequent reclassification 
based on ORCA criteria as part of the ZHIAS classification 
Drug interaction classifications 
Frequency of 
distinct 
combinations in 
484 patients 
Frequency of 
interaction alerts in 
484 patients 
 n % n % 
MediQ level 3 (“high danger”) 8 100.0 8 100.0 
    ORCA level 1 (“contraindicated”) 2 25.0 2 25.0 
    ORCA level 2 (“provisionally 
contraindicated”) 1 12.5 1 12.5 
    ORCA level 3 (“conditional risk”) 5 62.5 5 62.5 
    ORCA level 4 (“minimal risk”) 0 0.0 0 0.0 
     
MediQ level 2 (“average danger”) 164 100.0 518 100.0 
    ORCA level 1 (“contraindicated”) 3 1.8 3 0.6 
    ORCA level 2 (“provisionally 
contraindicated”) 19 11.6 29 5.6 
    ORCA level 3 (“conditional risk”) 85 51.8 272 52.5 
    ORCA level 4 (“minimal risk”) 57 34.8 214 41.3 
     
MediQ level 1 (“low danger”) 486 100.0 1’233 100.0 
    ORCA level 1 (“contraindicated”) 1 0.2 1 0.1 
    ORCA level 2 (“provisionally 
contraindicated”) 3 0.6 3 0.2 
    ORCA level 3 (“conditional risk”) 37 7.6 50 4.1 
    ORCA level 4 (“minimal risk”) 445 91.6 1179 95.6 
     
MediQ level 0 (“no interaction”) 454 100.0 1’004 100.0 
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Table 4 - Summary of full ZHIAS classification stratified over ORCA classes 1 to 3 for all 
interactions identified by MediQ with corresponding frequencies in 484 analyzed patients 
ZHIAS classification 
Frequencies in 484 patients, stratified over ORCA 
classes 
 ORCA 1 
(contraindicated) 
ORCA 2 
(provisionally 
contraindicated) 
ORCA 3 
(conditional risk) 
 n (%) n (%) n (%) 
TOTAL combinations 6 (100.0) 33 (100.0) 327 (100.0) 
    
Management    
Desired 0 (0.0) 22 (66.7) 191 (58.4) 
Consider alternative 6 (100.0) 12 (36.4) 131 (40.1) 
Monitoring 0 (0.0) 33 (100.0) 323 (98.8) 
    
Mechanism1    
Pharmacokinetic 4 (66.7) 14 (42.4) 103 (31.5) 
Pharnacodynamic 2 (33.3) 31 (93.9) 276 (84.4) 
    
Expected adverse 
effects    
Increased drug effect 2 (33.3) 26 (78.8) 210 (64.2) 
Decreased drug effect 4 (66.7) 4 (12.1) 53 (16.2) 
Sedation (CNS) 0 (0.0) 20 (60.6) 24 (7.3) 
Serotonin syndrome 0 (0.0) 2 (6.1) 17 (5.2) 
Extrapyramidal 
symptoms 0 (0.0) 4 (12.1) 3 (0.9) 
Seizures 0 (0.0) 4 (12.1) 17 (5.2) 
CNS effects other 0 (0.0) 3 (9.1) 32 (9.8) 
Nephrotoxicity 0 (0.0) 0 (0.0) 6 (1.8) 
Hepatotoxicity 0 (0.0) 0 (0.0) 13 (4.0) 
QTc prolongation 0 (0.0) 2 (6.1) 22 (6.7) 
Cardiac arrhythmias 0 (0.0) 6 (18.2) 33 (10.1) 
Thrombosis 0 (0.0) 0 (0.0) 5 (1.5) 
Bleeding 2 (33.3) 1 (3.0) 149 (45.6) 
Blood pressure up 0 (0.0) 1 (3.0) 6 (1.8) 
Blood pressure down 0 (0.0) 5 (15.2) 17 (5.2) 
Cardiovascular effects 
other 0 (0.0) 1 (3.0) 7 (2.1) 
Hyperkalemia 0 (0.0) 0 (0.0) 11 (3.4) 
Hypokalemia  0 (0.0) 0 (0.0) 6 (1.8) 
Hyponatremia 0 (0.0) 0 (0.0) 13 (4.0) 
Metabolic/endocrine 
effects  1 (16.7) 2 (6.1) 6 (1.8) 
Gastrointestinal toxicity 0 (0.0) 1 (3.0) 14 (4.3) 
Muscular toxicity 0 (0.0) 0 (0.0) 6 (1.8) 
Hematotoxicity 0 (0.0) 2 (6.1) 2 (0.6) 
Allergy/skin reactions 0 (0.0) 0 (0.0) 15 (4.6) 
Other 0 (0.0) 0 (0.0) 3 (0.9) 
1 Categories are not mutually exclusive and can therefore exceed 100%. 
21 
 
 
 
Table 5 -  Presentation of all specific interactions with the highest rating according to MediQ or 
ZHIAS, i.e. for MediQ grade 3, “high danger”, or for ZHIAS ORCA grade 1, “contraindicated”1 
1 Each listed combination occurred only once in the studied population 
2 ORCA notation: 1 = contraindicated, 2 = provisionally contraindicated, 3 = conditional risk.  
Assignment to ORCA class 1 “contraindicated” does not necessarily imply a high risk of an ADE. 
It means that the risk also outweighs the benefit, i.e. the assignment can primarily be driven by 
limited evidence on a drug’s benefit, such as for gingko biloba. 
3 A = consider an available alternative; D = desired interaction; M = special monitoring 
recommended 
 
 
 
 
 
 
 
 
 
  ZHIAS classification 
Drug combination2 
MediQ 
danger 
ORC
A 
Managemen
t3 
Expected adverse effects 
Atazanavir - omeprazole High 1 A Loss of atazanavir efficacy 
Midazolam p.o. - 
carbamazepine High 1 A Loss of midazolam efficacy 
Haloperidol - sulpiride High 2 D / M EPS, QTc prolongation 
Acetylsalicylic acid low dose 
– methotrexate low dose 
High 3 A / M Bone marrow toxicity 
Fluoxetine - tramadol High 3 A / M 
Serotonin syndrome, 
seizures 
Paroxetine - venlafaxine High 3 D / M Serotonin syndrome, QTc 
Phenytoin - valproate High 3 D / M Sedation, hepatotoxicity 
Lisinopril - spironolactone High 3 A / M Hyperkalemia 
Gingko biloba - dalteparin Average 1 A Bleeding 
Midazolam - St. John’s wort Average 1 A Loss of efficacy 
Olanzapine - carbamazepine Average 1 A Loss of efficacy, metabolic 
Ginkgo biloba - acetylsalicylic 
acid Low 1 A Bleeding 
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Table 6 - Presentation of the 5 most frequent specific drug interactions classified by ZHIAS as 
ORCA 2 (“provisionally contraindicated”), and the 10 most frequent combinations classified by 
ZHIAS as ORCA 3 (“conditional risk”) in 484 analyzed patients. 
   ZHIAS classification 
Combination name Frequency 
in 
484 patients 
MediQ 
danger 
ORCA1 Manageme
nt2 
Expected 
adverse effects 
 n %     
5 most frequent combinations classified as “provisionally contraindicated” by ZHIAS 
Any combination of two 
benzodiazepines 
12 2.5 Average 
or low 
2 D / M Sedation 
Metoprolol - amiodarone 4 0.8 Average 2 A / M Hypotension, 
bradycardia 
Zolpidem and any 
benzodiazepine 
4 0.8 Average 
or low 
2 D / M Sedation 
Carbamazepine - 
metoclopramide 
2 0.4 Average 2 A / M Seizures, other 
CNS effects 
Carbamazepine - 
tramadol 
2 0.4 Average 2 A / M Sedation, 
seizures, loss of 
analgesia 
10 most frequent combinations classified as “conditional risk” by ZHIAS 
Acetylsalicylic acid (low 
dose) - heparins 
140 28.9 Average 3 D / M Bleeding 
Acetylsalicylic acid - 
corticosteroids 
11 2.3 Average 3 A / M GI ulceration 
Lamotrigine - valproate 9 1.9 Average 3 D / M Other CNS 
effects, skin 
reactions 
Carbamazepine - 
paracetamol 
7 1.4 Average 3 A / M Hepatotoxicity 
Levothyroxine – calcium 
or magnesium hydroxide 
7 1.4 Average or 
low 
3 M Loss of thyroid 
hormone efficacy 
Tramadol - tricyclic 
antidepressants 
5 1.0 Average 3 A / M Serotonin 
syndrome, 
seizures 
Amlodipine - metoprolol 4 0.8 Average 3 D / M Hypotension, 
bradycardia 
Atorvastatin- amiodarone 4 0.8 Average 3 A / M Muscle toxicity 
Clonazepam - valproate 4 0.8 Low 3 D / M Absence seizures, 
sedation 
Carbamazepine - 
lamotrigine 
3 0.6 Average 3 D / M Other CNS 
effects, skin 
reactions 
Citalopram - 
hydrochlorothiazide 
3 0.6 Low 3 A / M Hyponatremia 
1 ORCA notation: 1 = contraindicated, 2 = provisionally contraindicated, 3 = conditional risk.  
2 Management notation: A = consider an available alternative; D = desired interaction; M = 
special monitoring recommended 
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8. Figures  
Figure 1: Overview of the study procedur  
 
 
Figure 2: Interaction grading according  to MediQ and after ZHIAS reclassification 
 
 
The presented distributions are based on individual patients where each patient is counted only 
once and assigned according to the interaction with the highest grade found in that patient. 
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